Fargnoli, Maria Concetta
 Distribuzione geografica
Continente #
NA - Nord America 3.955
AS - Asia 3.060
EU - Europa 1.726
SA - Sud America 622
Continente sconosciuto - Info sul continente non disponibili 154
AF - Africa 106
OC - Oceania 5
Totale 9.628
Nazione #
US - Stati Uniti d'America 3.808
SG - Singapore 1.544
CN - Cina 560
BR - Brasile 509
IT - Italia 362
SE - Svezia 302
VN - Vietnam 248
DE - Germania 232
FR - Francia 195
IN - India 137
IE - Irlanda 122
GB - Regno Unito 121
HK - Hong Kong 117
JP - Giappone 104
ID - Indonesia 87
FI - Finlandia 86
RU - Federazione Russa 69
BD - Bangladesh 66
CA - Canada 66
MX - Messico 39
AR - Argentina 37
AT - Austria 32
KR - Corea 31
BE - Belgio 27
ES - Italia 27
PL - Polonia 27
CI - Costa d'Avorio 26
ZA - Sudafrica 26
NL - Olanda 25
IQ - Iraq 24
TR - Turchia 23
CO - Colombia 21
CZ - Repubblica Ceca 21
EC - Ecuador 19
SA - Arabia Saudita 15
CH - Svizzera 14
PK - Pakistan 14
VE - Venezuela 14
UA - Ucraina 13
KE - Kenya 12
JM - Giamaica 11
MY - Malesia 11
RO - Romania 11
AE - Emirati Arabi Uniti 10
EG - Egitto 9
UZ - Uzbekistan 9
LT - Lituania 8
MA - Marocco 8
PE - Perù 8
CR - Costa Rica 7
JO - Giordania 7
PH - Filippine 7
CL - Cile 6
KZ - Kazakistan 6
IL - Israele 5
TN - Tunisia 5
DZ - Algeria 4
GT - Guatemala 4
LB - Libano 4
AL - Albania 3
AU - Australia 3
BM - Bermuda 3
BS - Bahamas 3
DK - Danimarca 3
GH - Ghana 3
IR - Iran 3
NG - Nigeria 3
NO - Norvegia 3
NP - Nepal 3
PA - Panama 3
PS - Palestinian Territory 3
PY - Paraguay 3
SC - Seychelles 3
TW - Taiwan 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
EU - Europa 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
Totale 9.456
Città #
Singapore 854
Chandler 420
San Jose 410
Ashburn 367
Dallas 173
Beijing 156
New York 130
Dublin 122
Hong Kong 113
Ann Arbor 98
Tokyo 98
Los Angeles 91
Lauterbourg 90
Jakarta 80
Hefei 79
Milan 79
Ho Chi Minh City 73
Hanoi 68
Boston 64
Hyderabad 64
Rome 58
Bremen 56
Frankfurt am Main 56
Princeton 52
Helsinki 51
São Paulo 47
San Mateo 46
Chicago 45
The Dalles 39
Munich 38
Moscow 37
Santa Clara 36
Wilmington 34
Seoul 30
London 29
St Louis 29
Atlanta 27
Brooklyn 27
Houston 27
Abidjan 26
Kent 26
Nuremberg 25
Brussels 24
Orem 23
North Bergen 22
Montreal 21
Paris 21
Lappeenranta 20
Mexico City 20
Buffalo 18
Woodbridge 18
Denver 17
Washington 17
Phoenix 16
Vienna 16
Brno 15
Council Bluffs 15
Poplar 15
Seattle 15
Cattolica 14
Rio de Janeiro 14
San Francisco 14
Toronto 14
Warsaw 14
Amsterdam 13
Da Nang 13
Düsseldorf 13
Chennai 12
Philadelphia 12
Portsmouth 12
Stockholm 12
Belo Horizonte 11
Falkenstein 11
Jacksonville 11
Johannesburg 11
Nairobi 11
Turku 11
Wroclaw 11
Baghdad 10
Boardman 10
Mumbai 10
Nanjing 10
New Delhi 10
Bogotá 9
Brasília 9
Curitiba 9
Haiphong 9
Jeddah 9
Kingston 9
Manchester 9
Newark 9
Redwood City 9
Ribeirão Preto 9
Saint Cloud 9
Elk Grove Village 8
Las Vegas 8
Mountain View 8
Quito 8
Tashkent 8
Amman 7
Totale 5.213
Nome #
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 271
Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study 210
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis 174
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023 168
Sclerosing nevus with pseudomelanomatous features: dermoscopic and confocal aspects 163
Real-world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 160
Cutaneous squamous cell carcinoma. Italian guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines 156
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023 150
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 146
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 139
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention 135
Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic Approaches 133
Pruritus characteristics in a large Italian cohort of psoriatic patients 131
Management of cutaneous melanoma: Comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology 130
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 129
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 129
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 122
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 121
Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies 120
Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness 116
Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients 114
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 112
"Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference 111
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019 111
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 110
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study 110
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 109
Characterization of melanoma susceptibility genes in high-risk patients from Central Italy 109
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 109
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 109
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study–IL PSO (Italian Landscape Psoriasis) 108
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 107
5-aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an italian study in the real-life setting 107
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 106
Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma 105
Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in italy 105
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 104
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 103
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 103
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study 103
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition 103
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 102
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 102
Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities 101
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 101
The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 100
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 100
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 99
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019 99
Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study 98
Molecular alterations in basal cell carcinoma subtypes 96
Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi 94
Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family 94
Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis 93
Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study 92
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 92
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 91
"Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference 90
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas 90
Mycosis fungoides: creation of a prospective, interdisciplinary and multicenter study in central Italy 89
Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma 89
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 88
ΜelanoQ: A Consensus Questionnaire of Standardized Epidemiologic and Clinical Variables for Melanoma Risk Assessment by the MelaNostrum Consortium 87
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022 86
Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’ 86
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 86
Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w) 85
Telomeres and telomerase in cutaneous squamous cell carcinoma 84
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 83
Update on the Management of Pediatric Psoriasis: An Italian Consensus 83
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 82
Response to: Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’ 81
Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018)) 81
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 80
Long-term efficacy and safety of daylight photodynamic therapy with methyl amninolevulinate for actinic keratosis of the face and scalp 80
AtopyReg®: the prospective Italian patient registry for moderate to severe atopic dermatitis in adults by SIDeMaST 78
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 78
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study 76
Contribution of common genetic variants to familial aggregation of disease and implications for sequencing studies 76
Italian expert consensus paper on the management of patients with actinic keratoses 76
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 75
Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas 69
Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia 68
High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium 67
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results 64
The association between COVID-19 lockdowns and melanoma diagnosis and thickness: A multicenter retrospective study from Europe 64
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience 58
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 57
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study 54
Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls 54
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis) 53
Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics 50
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients—IL PSO (Italian Landscape Psoriasis) 47
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 45
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 43
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis) 31
Totale 9.628
Categoria #
all - tutte 44.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.849


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022422 0 0 8 17 29 8 1 66 32 35 111 115
2022/20231.023 111 134 75 184 77 124 29 86 146 16 31 10
2023/2024751 26 184 52 54 47 104 55 10 15 27 88 89
2024/20251.762 41 28 107 56 151 115 60 77 268 206 363 290
2025/20264.524 604 226 238 497 771 266 714 211 316 291 169 221
2026/2027761 167 378 216 0 0 0 0 0 0 0 0 0
Totale 9.628